What does 2026 hold for bioanalysis?

As we move into 2026, we review key bioanalytical trends and activities to look out for this year. In 2025, the FDA’s Center for Drug Evaluation and Research (CDER; MD, USA) approved 46 new therapeutic agents, marginally down from 50 in 2024 [1]. Small molecules continued to dominate approvals, accounting for 31 approvals, followed by proteins at 12 and oligonucleotides with three [1]. These approvals came despite widespread restructuring and budget cuts within the US health and research department, with 18% of the FDA’s CDER and CBER workforce being cut or pushed to quit in the first 9 months of...